drugset / Trial / NCT00731198
Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)
RandomizedParallel-groupSingle-blindPrevention
Summary
The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.
Timeline
- Start
- 2008-08
- Primary completion
- 2009-03
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Drotaverine | Small molecule | 40 mg | Intravenous |
| Comparator | Hyoscine butylbromide | Unknown | 20 mg | Intravenous |